All In Biotech

Drug Trial Radar · NCT03303339

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

72

Actual

Start

Nov 17, 2017

Primary completion

Nov 17, 2021

Study completion Nov 17, 2021

Sponsor

Lead sponsor
Cardiff OncologyIndustry
Sponsor type
Industry
First posted
Oct 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the phase 1b/2 study is to determine whether Onvansertib given orally daily for 5 consecutive days every 28 days is safe and tolerable in adult patients who have relapsed/refractory Acute Myeloid Leukemia (AML), or are ineligible for intensive induction therapy, and to determine the maximum tolerated dose and recommended phase 2 dose of Onvansertib in combination with decitabine or Onvansertib in combination with low-dose cytarabine. In the phase 2 portion of the study, Onvansertib in combination with decitabine will be studied to provide further data on the safety profile of the combination and to preliminarily assess the activity of the chosen combination in patients with untreated AML who are not candidates for aggressive induction therapy, or who have received one prior treatment for their AML.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • OnvansertibDrug

    Onvansertib orally

  • CytarabineDrug

    subcutaneously

  • DecitabineDrug

    intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose Limiting Toxicities (DLT)Time frame: Up to Day 28 of Cycle 1
  2. Number of Participants With Change From Baseline in Eastern Co-operative Oncology Group (ECOG) Performance StatusTime frame: Baseline and end of study (approximately up to up to 27 months)
  3. Phase 2: Number of Participants Who Achieved a Complete Response (CR)Time frame: Up to 27 months
  4. Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 30 days after last dose of study drug (up to 27 months)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Yale University

    New Haven, Connecticut

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Allina Health Virginia Piper Cancer Institute

    Minneapolis, Minnesota

  • Roswell Park Cancer Institute

    Buffalo, New York

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists - Fairfax Office

    Fairfax, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.